Search

Your search keyword '"Nishibori, Masahiro"' showing total 1,011 results
Start Over Author "Nishibori, Masahiro"
1,011 results on '"Nishibori, Masahiro"'

8. Continuous mild stimulation with advanced glycation end products reduce aggrecan and type II collagen production via the RAGE without inducing cell death in human OUMS-27 chondrosarcoma cells

Author

Hatipoglu, Omer Faruk, primary, Nishinaka, Takashi, additional, Yaykasli, Kursat Oguz, additional, Mori, Shuji, additional, Watanabe, Masahiro, additional, Toyomura, Takao, additional, Nishibori, Masahiro, additional, Hirohata, Satoshi, additional, Takahashi, Hideo, additional, and Wake, Hidenori, additional

Published
2024
Full Text
View/download PDF

21. Perineural Treatment with High Mobility Group Box-1 Monoclonal Antibody Prevents Initiation of Pain-Like Behaviors in Female Mice with Trigeminal Neuropathy

Author

Ma, Simeng, primary, Nakamura, Yoki, additional, Kochi, Takahiro, additional, Uemoto, Suzuna, additional, Hisaoka-Nakashima, Kazue, additional, Wang, Dengli, additional, Liu, Keyue, additional, Wake, Hidenori, additional, Nishibori, Masahiro, additional, and Morioka, Norimitsu, additional

Published
2024
Full Text
View/download PDF

23. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis

Author

Araki, Kota, Kinoshita, Rie, Tomonobu, Nahoko, Gohara, Yuma, Tomida, Shuta, Takahashi, Yuta, Senoo, Satoru, Taniguchi, Akihiko, Itano, Junko, Yamamoto, Ken-ichi, Murata, Hitoshi, Suzawa, Ken, Shien, Kazuhiko, Yamamoto, Hiromasa, Okazaki, Mikio, Sugimoto, Seiichiro, Ichimura, Kouichi, Nishibori, Masahiro, Miyahara, Nobuaki, Toyooka, Shinichi, and Sakaguchi, Masakiyo

Published
2021
Full Text
View/download PDF

24. Anti-HMGB1 mAb Therapy Reduces Epidural Hematoma Injury.

Author

Gao, Shangze, Wang, Dengli, Liu, Keyue, Tomono, Yasuko, Fu, Li, Gao, Yuan, Takahashi, Yohei, Yata, Mariko, and Nishibori, Masahiro

Subjects
EPIDURAL hematoma, TUMOR necrosis factors, NITRIC-oxide synthases, BRAIN injuries, NERVE tissue, MONOCLONAL antibodies, CYTOPLASM
Abstract

Epidural and subdural hematomas are commonly associated with traumatic brain injury. While surgical removal is the primary intervention for these hematomas, it is also critical to prevent and reduce complications such as post-traumatic epilepsy, which may result from inflammatory responses in the injured brain areas. In the present study, we observed that high mobility group box-1 (HMGB1) decreased in the injured brain area beneath the epidural hematoma (EDH) in rats, concurrent with elevated plasma levels of HMGB1. Anti-HMGB1 monoclonal antibody therapy strongly inhibited both HMGB1 release and the subsequent increase in plasma levels. Moreover, this treatment suppressed the up-regulation of inflammatory cytokines and related molecules such as interleukin-1-beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and inducible nitric oxide synthase (iNOS) in the injured areas. Our in vitro experiments using SH-SY5Y demonstrated that hematoma components—thrombin, heme, and ferrous ion— prompted HMGB1 translocation from the nuclei to the cytoplasm, a process inhibited by the addition of the anti-HMGB1 mAb. These findings suggest that anti-HMGB1 mAb treatment not only inhibits HMGB1 translocation but also curtails inflammation in injured areas, thereby protecting the neural tissue. Thus, anti-HMGB1 mAb therapy could serve as a complementary therapy for an EDH before/after surgery. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Cationic ribosomal proteins can inhibit pro‐inflammatory action stimulated by LPS+HMGB1 and are hindered by advanced glycation end products.

Author

Watanabe, Masahiro, Toyomura, Takao, Wake, Hidenori, Nishinaka, Takashi, Hatipoglu, Omer Faruk, Takahashi, Hideo, Nishibori, Masahiro, and Mori, Shuji

Subjects
ADVANCED glycation end-products, BASIC proteins, RECEPTOR for advanced glycation end products (RAGE), RIBOSOMAL proteins, PEPTIDES
Abstract

We previously found that ribosomal protein L9 (RPL9) is a novel advanced glycation end product (AGE)‐binding protein that can decrease pro‐inflammatory TNF‐α expression stimulated by lipopolysaccharide (LPS) plus high‐mobility group box 1 (HMGB1), suggesting that RPL9 has a role in regulating LPS+HMGB1‐stimulated inflammatory reactions. Among the various ribosomal proteins, it was found that RPS5 reproduced the regulatory activity of RPL9 on LPS+HMGB1‐stimulated TNF‐α expression in macrophage‐like RAW264.7 cells. RPL9 and RPS5 share a common feature as cationic proteins. Polylysine, a cationic polypeptide, and a synthetic peptide of the cationic region from RPL9 also exhibited reducing activity on LPS+HMGB1‐induced TNF‐α expression. By pull‐down assay, RPL9 and RPS5 were confirmed to interact with AGEs. When AGEs coexisted with LPS, HMGB1, plus RPL9 or RPS5, the reducing effect of TNF‐α expression by these cationic ribosomal proteins was shown to be abrogated. The results suggest that cationic ribosomal proteins have a regulatory role in the pro‐inflammatory response induced by LPS+HMGB1, and in the pathophysiological condition of accumulating AGEs, this regulatory effect is abolished, which exacerbates inflammation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness

Author

Chen, Youyi, Sumardika, I Wayan, Tomonobu, Nahoko, Kinoshita, Rie, Inoue, Yusuke, Iioka, Hidekazu, Mitsui, Yosuke, Saito, Ken, Ruma, I Made Winarsa, Sato, Hiroki, Yamauchi, Akira, Murata, Hitoshi, Yamamoto, Ken-ichi, Tomida, Shuta, Shien, Kazuhiko, Yamamoto, Hiromasa, Soh, Junichi, Futami, Junichiro, Kubo, Miyoko, Putranto, Endy Widya, Murakami, Takashi, Liu, Ming, Hibino, Toshihiko, Nishibori, Masahiro, Kondo, Eisaku, Toyooka, Shinichi, and Sakaguchi, Masakiyo

Published
2019
Full Text
View/download PDF

41. Consistently low levels of histidine-rich glycoprotein as a new prognostic biomarker for sepsis: A multicenter prospective observational study

Author

Kawanoue, Naoya, Kuroda, Kosuke, Yasuda, Hiroko, Oiwa, Masahiko, Suzuki, Satoshi, Wake, Hidenori, Hosoi, Hiroki, Nishibori, Masahiro, Morimatsu, Hiroshi, Kawanoue, Naoya, Kuroda, Kosuke, Yasuda, Hiroko, Oiwa, Masahiko, Suzuki, Satoshi, Wake, Hidenori, Hosoi, Hiroki, Nishibori, Masahiro, and Morimatsu, Hiroshi

Abstract

Background Few sepsis biomarkers accurately predict severity and mortality. Previously, we had reported that first-day histidine-rich glycoprotein (HRG) levels were significantly lower in patients with sepsis and were associated with mortality. Since the time trends of HRG are unknown, this study focused on the time course of HRG in patients with sepsis and evaluated the differences between survivors and non-survivors. Methods A multicenter prospective observational study was conducted involving 200 patients with sepsis in 16 Japanese hospitals. Blood samples were collected on days 1, 3, 5, and 7, and 28-day mortality was used for survival analysis. Plasma HRG levels were determined using a modified quantitative sandwich enzyme-linked immunosorbent assay. Results First-day HRG levels in non-survivors were significantly lower than those in survivors (mean, 15.7 [95% confidence interval (CI), 13.4-18.1] vs 20.7 [19.5-21.9] mu g/mL; P = 0.006). Although there was no time x survivors/non-survivors interaction in the time courses of HRG (P = 0.34), the main effect of generalized linear mixed models was significant (P < 0.001). In a univariate Cox proportional hazards model with each variable as a time-dependent covariate, higher HRG levels were significantly associated with a lower risk of mortality (hazard ratio, 0.85 [95% CI, 0.78-0.92]; P < 0.001). Furthermore, presepsin levels (P = 0.02) and Sequential Organ Function Assessment scores (P < 0.001) were significantly associated with mortality. Harrell's C-index values for the 28-day mortality effect of HRG, presepsin, procalcitonin, and C-reactive protein were 0.72, 0.70, 0.63, and 0.59, respectively. Conclusions HRG levels in non-survivors were consistently lower than those in survivors during the first seven days of sepsis. Repeatedly measured HRG levels were significantly associated with mortality. Furthermore, the predictive power of HRG for mortality may be superior to that of other

Published
2023

44. Identification of cells that release HMGB1 responsible for colonic hypersensitivity in a mouse model for irritable bowel syndrome and its prevention by azeliragon, a RAGE antagonist, and sulfasalazine, an anti-arthritis/anti-colitis medicine

Author

Tsubota, Maho, primary, Sasaki, Kana, additional, Shin, Eunkyung, additional, Okamura, Yuta, additional, Domoto, Risa, additional, Sekiguchi, Fumiko, additional, Okada, Takuya, additional, Toyooka, Naoki, additional, Tomono, Yasuko, additional, Nishibori, Masahiro, additional, and Kawabata, Atsufumi, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results